Predictive Oncology Inc. together with Cancer Research Horizons announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology's PEDAL(TM) platform. The collaboration will utilize Predictive Oncology's PEDAL technology to evaluate Cancer Research Horizons' pre-clinical drug inhibitors of Glutaminase in order to determine which cancer types and patient populations are most likely to respond to treatment with these compounds. PEDAL is an artificial intelligence and machine learning platform which makes high-confidence drug response predictions enabling a more informed selection of drug-tumor type combinations for clinical development.

PEDAL increases the probability of clinical success by efficiently addressing tumor heterogeneity during pre-clinical stages.